ATAI Life Sciences NV (STU:9VC)
€ 1.0905 0.1125 (11.5%) Market Cap: 181.10 Mil Enterprise Value: 118.25 Mil PE Ratio: 0 PB Ratio: 1.18 GF Score: 44/100

ATAI Life Sciences NV at Citi Biopharma Co-Panel Day (Virtual) Transcript

May 18, 2022 / NTS GMT
Release Date Price: €3.88 (+0.39%)
Neena Marie Bitritto;Garg;Srinivas G. Rao<
Citigroup Inc., Research Division - VP & Analyst

All right. Hi, everybody. Thank you for joining today's virtual company panel day. If you don't know me, my name is Neena Bitritto-Garg. I'm one of the biotech analysts here at Citi.

And for our next panel, we'll be discussing mood disorders and mental health. And I'm really pleased to be joined by executives from 4 companies working in the space, including at Atai Life Sciences, Bionomics, COMPASS Pathways and Praxis Precision Medicines.

And before we do get into Q&A, I just wanted to flag that if you do have any questions, you can feel free to send me an e-mail directly. My email address is listed on the webcast. You can find me on Bloomberg and ping me that way, whatever works for you.

So now I just wanted to turn it over to our panelists. Maybe if we go alphabetically by company names. So maybe Srini, if you want to start, introduce yourself and give some opening remarks on Atai and then we can go around, yes, alphabetically by company name.

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot